Xtant Medical Holdings

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xtant Medical Holdings reports robust Q1 growth and raises guidance

Xtant Medical Holdings delivered strong revenue growth in Q1 2024, with a focus on strategic initiatives for future expansion and market penetration.
While facing challenges in supply chain and product cannibalization, the company's emphasis on new products and acquisitions bodes well for long-term growth.
With an increased revenue guidance for 2024 and a positive adjusted EBITDA, Xtant is poised for accelerated organic growth and improved financial performance.

Xtant Medical Holdings reports robust Q2 growth and strategic focus

Xtant Medical Holdings is on track to achieve full-year revenue guidance of $116 million to $120 million.
The company's focus on new products, acquisitions, and operational efficiency bodes well for long-term growth.
Despite challenges in organic growth and net loss, Xtant is strategically positioned for sustainable expansion.

Xtant Medical Holdings reports solid Q3 growth amidst product challenges

Xtant Medical Holdings showed growth in Q3 despite challenges with product delays.
The company is focused on profitability, self-sustainability, and doubling in size by 2024.
Strategic moves like bringing manufacturing in-house and new product releases position Xtant for future growth.
Anticipates revenue growth, margin improvement, and aims for EBITDA positivity in Q4.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.

BELGRADE, Mont., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2020.

Xtant Medical Announces Third Quarter 2020 Financial Results

BELGRADE, Mont., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has set November 5, 2020 as the record date for its previously-announced proposed rights offering of up to $15 million of shares of its common stock and the expected subscription period.

Xtant Medical Announces Record Date and Other Key Dates for Proposed $15 Million Rights Offering

BELGRADE, Mont., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2020, before the open of the financial markets on Thursday, October 29, 2020.

Xtant Medical to Issue Third Quarter 2020 Financial Results on October 29, 2020

BELGRADE, Mont., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it received notification from the NYSE American LLC yesterday that the Company has regained compliance with all of the continued listing standards, including in particular the requirement under NYSE American Company Guide Section 1003(a)(iii) that requires a listed issuer to maintain stockholders’ equity of at least $6 million if it has reported losses from continuing operations, and/or net losses, in its five most recent fiscal years.

Xtant Medical Regains Compliance with NYSE American Continued Listing Standards

Xtant Medical Holdings news on Friday has XTNT stock skyrocketing after the company announced the completion of their debt restructuring plan. The post XTNT Stock Skyrockets After Xtant Medical Holdings Restructures Debt appeared first on InvestorPlace.

XTNT Stock Skyrockets After Xtant Medical Holdings Restructures Debt

BELGRADE, Mont., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has completed its previously announced debt restructuring transaction.

Xtant Medical Announces Closing of Debt Restructuring

BELGRADE, Mont., Aug.  24, 2020  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the U.S. commercial launch of the Matriform® Si, a silicated synthetic bone graft strip designed and cleared for spinal fusion procedures.  The Matriform Si Strip is resorbable, osteoconductive, and has a cancellous bone-like structure.  It is prepared from Beta-tricalcium phosphate (β-TCP) and porcine collagen for its intended use in filling and bridging degenerative or traumatic bone defects.

Xtant Medical Announces U.S. Commercial Launch of the Matriform® Si for Spinal Fusion Procedures

PHILADELPHIA, Aug. 15, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Xtant Medical Holdings, Inc.

Kaskela Law LLC Announces Investigation of Xtant Medical Holdings, Inc. (XTNT) and Encourages XTNT Stockholders to Contact the Firm

BELGRADE, Mont., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has entered into a Restructuring and Exchange Agreement with the lenders under its credit facility pursuant to which the parties agreed to take certain actions to restructure Xtant’s outstanding indebtedness, including the exchange of certain indebtedness outstanding under the facility, together with accrued and unpaid interest thereon, into shares of Xtant common stock.

Xtant Medical Announces Debt Restructuring

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q2 2020 Results - Earnings Call Transcript

BELGRADE, Mont., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2020.

Xtant Medical Announces Second Quarter 2020 Financial Results

BELGRADE, Mont., July  30, 2020  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2020, after the close of the financial markets on Monday, August 3, 2020.

Xtant Medical to Issue Second Quarter 2020 Financial Results on August 3, 2020

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q1 2020 Results - Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q4 2019 Results - Earnings Call Transcript

Xtant Medical Holdings' (XTNT) CEO Sean Browne on Q3 2019 Results - Earnings Call Transcript

BELGRADE, Mont., Oct.  18, 2019  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, will feature its recently announced Intice™-C Titanium Cervical Interbody Spacer, Atrix-C Union™ Cervical Interbody Spacer and Calix®-C PC Plasma Coated PEEK Implant products at the Congress of Neurological Surgeons (CNS) Annual Meeting, which will be held October 19 – 23 in San Francisco.

Xtant Medical to Feature Innovative Product Offering at the CNS Annual Meeting

BELGRADE, Mont., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, plans to introduce three new products at the North American Spine Society (NASS) 2019 Annual Meeting, which will be held September 25 – 28 in Chicago. Meeting attendees can visit Booth #2916 to learn about Xtant Medical’s latest product innovation.

Xtant Medical Showcases Continued Innovation with Three New Product Introductions at NASS 2019

Xtant Medical Holdings, Inc. (XTNT) Management on Q2 2019 Results - Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q1 2019 Results - Earnings Call Transcript

Xtant Medical Holdings' (XTNT) Management on Q4 2018 Results - Earnings Call Transcript

News for Xtant Medical Holdings Stock (XTNT)